Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02437487 · ClinicalTrials.gov registry record · Phase 2
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
A Phase 2 study of Clostridium Difficile, sponsored by Seres Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 20
- Study locations
NCT02437487: Completed Phase 2 study of Clostridium Difficile, sponsored by Seres Therapeutics.
NCT02437487 is a Phase 2 study of Clostridium Difficile that has completed, run by Seres Therapeutics. The registered enrollment target is 89 participants, below the 447-participant average among 6 other Clostridium Difficile trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02437487, a Phase 2 study of Clostridium Difficile, has completed, sponsored by Seres Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SER-109
Study Locations (20)
Florida
- ZASA Clinical Research - Atlantis
- Omega Research Consultants LLC - DeBary
- Borland-Groover Clinic - Jacksonville
- Gastroenterology Group of Naples - Naples
- Advanced Medical Research Center - Port Orange
California
- North County Gastroenterology - Oceanside
- University Of California Davis - Sacramento
- Ventura Clinical Trials - Ventura
Maryland
- Anne Arundel Health System Research Institute - Annapolis
- Johns Hopkins Bayview Medical - Baltimore
- Metropolitan Gastroenterolgy Group Pc - Chevy Chase
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Med Cntr - Boston
Georgia
- Emory University - Atlanta
Idaho
- Idaho Falls Infection Diseases - Idaho Falls
Louisiana
- Ochsner Clinic Foundation - New Orleans
Michigan
- William Beaumont Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
What the finished NCT02437487 record still lists
NCT02437487 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 447-participant average among 6 other Clostridium Difficile trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Clostridium Difficile appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02437487 names 20 study sites across 11 states, led by Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT02437487 about?
NCT02437487 is a clinical study titled "SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)". The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.
What is the current status of trial NCT02437487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2015-05. Estimated completion is 2016-10.
What conditions does trial NCT02437487 study?
This clinical trial studies the following conditions: Clostridium Difficile.
What interventions are being tested in trial NCT02437487?
The interventions under investigation include: Placebo (DRUG), SER-109 (DRUG).
Who is sponsoring clinical trial NCT02437487?
This trial is sponsored by Seres Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02437487 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
COMPLETED · Phase 2
-
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
COMPLETED · Phase 2
-
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
RECRUITING · Phase 3
-
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
RECRUITING
-
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
ACTIVE NOT RECRUITING
-
Early FMT for C.Difficile
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia